Entegrion to develop blood product for U.S. Navy

08/26/2011 | MedCityNews.com

North Carolina biotech firm Entegrion is set to receive $9.84 million from the Navy for the development of a single blood product that has the potential to save lives on the battlefield. The product will combine two experimental blood products: Resusix, a freeze-dried human plasma designed to serve as an alternative to fresh-frozen plasma, and Stasix, a freeze-dried product based on blood platelets.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD